ALNY vs KRYS · P/E 76, rev $1.29B vs P/E 46, rev $235.6M
Alnylam Pharmaceuticals Inc (ALNY) versus Krystal Biotech Inc (KRYS) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Krystal Biotech Inc (KRYS) is a biotechnology company listed on NASDAQ.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported KRYS revenue for 2026-06-30 was $235.6M. Net income was $110.7M. KRYS currently screens at market cap $10.17B and trailing P/E 46.1.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. KRYS currently screens at market cap $10.17B and trailing P/E 46.1.
Not investment advice. Open the ALNY and KRYS stock pages for the full models.
Not investment advice.